EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Integration of Organoids With CRISPR Screens: A Narrative Review

Rushikesh Mukhare, Khushboo A Gandhi, Anushree Kadam, Aishwarya Raja, Ankita Singh, Mrudula Madhav, Rohan Chaubal, Shwetali Pandey, Sudeep Gupta

Biology of the Cell · 2025

DOI: 10.1111/boc.70006 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biology of the Cell, 2025. Verfasst von Rushikesh Mukhare und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Genomics and Hypoxia Lab (Clinician Scientist Laboratory), Advanced Centre for Treatment, Research, and Education in Cancer, Tata Memorial C…. Hauptthemen laut MEDLINE: Organoids, CRISPR-Cas Systems, Neoplasms. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Organoids represent a significant advancement in disease modeling, demonstrated by their capacity to mimic the physiological/pathological structure and functional characteristics of the native tissue. Recently CRISPR/Cas9 technology has emerged as a powerful tool in combination with organoids for the development of novel therapies in preclinical settings. This review explores the current literature on applications of pooled CRISPR screening in organoids and the emerging role of these models in understanding cancer. We highlight the evolution of genome‐wide CRISPR gRNA library screens in organoids, noting their increasing adoption in the field over the past decade. Noteworthy studies utilizing these screens to investigate oncogenic vulnerabilities and developmental pathways in various organoid systems are discussed. Despite the promise organoids hold, challenges such as standardization, reproducibility, and the complexity of data interpretation remain. The review also addresses the ideas of assessing tumor organoids (tumoroids) against established cancer hallmarks and the potential of studying intercellular cooperation within these models. Ultimately, we propose that organoids, particularly when personalized for patient‐specific applications, could revolutionize drug screening and therapeutic approaches, minimizing the reliance on traditional animal models and enhancing the precision of clinical interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OrganoidsCRISPR-Cas SystemsNeoplasmsHumansAnimalsGene Editing

Stichwörter der Autor:innen

clustered regularly interspaced short palindromic repeats (CRISPR)librariesneoplasmsorganoidpersonalized medicinescreening

Autor:innen und Institutionen

  • Clinical Genomics and Hypoxia Lab (Clinician Scientist Laboratory), Advanced Centre for Treatment, Research, and Education in Cancer, Tata Memorial Centre, Navi Mumbai, Maharashtra, India.
  • Training School Complex, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
  • Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Mumbai, Maharashtra, India.
  • Department of Surgical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Mumbai, Maharashtra, India.

Zitieren

APA

Mukhare, R., Gandhi, K. A., Kadam, A., Raja, A., Singh, A., Madhav, M., Chaubal, R., Pandey, S., & Gupta, S. (2025). Integration of Organoids With CRISPR Screens: A Narrative Review. Biology of the Cell. https://doi.org/10.1111/boc.70006

Vancouver

Mukhare R, Gandhi KA, Kadam A, Raja A, Singh A, Madhav M, et al. Integration of Organoids With CRISPR Screens: A Narrative Review. Biology of the Cell. 2025. doi:10.1111/boc.70006

BibTeX
@article{Mukhare2025,
  author = {Mukhare, Rushikesh and Gandhi, Khushboo A and Kadam, Anushree and Raja, Aishwarya and Singh, Ankita and Madhav, Mrudula and Chaubal, Rohan and Pandey, Shwetali and Gupta, Sudeep},
  title = {Integration of Organoids With CRISPR Screens: A Narrative Review},
  journal = {Biology of the Cell},
  year = {2025},
  doi = {10.1111/boc.70006}
}
Kostenlos starten →